| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Taro Pharmaceutical Indus (NYSE:TARO) is set to give its latest quarterly earnings report on Thursday, 2024-01-25. Here's what investors need to know before the announcement.
Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.30.
Taro Pharmaceutical Indus bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Last quarter the company beat EPS by $0.20, which was followed by a 2.3% drop in the share price the next day.
Here's a look at Taro Pharmaceutical Indus's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | 0.18 | 0.31 | 0.31 | 0.87 |
| EPS Actual | 0.38 | 0.40 | 0.18 | 0.19 |
| Price Change % | -2.3% | 0.11% | -5.68% | -1.26% |
Shares of Taro Pharmaceutical Indus were trading at $42.07 as of January 23. Over the last 52-week period, shares are up 37.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TARO
